Published in Urology on August 01, 1998
Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells. Mol Med (2008) 0.93
Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors. Mol Med (1999) 0.81
Evidence for the Possible Biological Significance of the igf-1 Gene Alternative Splicing in Prostate Cancer. Front Endocrinol (Lausanne) (2013) 0.80
The complexity of the IGF1 gene splicing, posttranslational modification and bioactivity. Mol Med (2014) 0.79
Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen. Clin Exp Metastasis (1999) 0.79
Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy. J Musculoskelet Neuronal Interact (2007) 1.26
Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved. Prostate (1991) 1.04
Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro. In Vivo (2009) 1.01
Mast cell-tumor cell interactions: for or against tumour growth and metastasis? Anticancer Res (1997) 0.97
In vivo models for heart failure research. In Vivo (2009) 0.97
Discovery of the mitotic selective chromatid segregation phenomenon and its implications for vertebrate development. Curr Opin Cell Biol (2010) 0.96
Epigenetic regulation on gene expression induced by physical exercise. J Musculoskelet Neuronal Interact (2013) 0.96
Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med (1993) 0.96
Wnt signaling in cardiovascular physiology. Trends Endocrinol Metab (2012) 0.95
Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol (1993) 0.92
Loss of heterozygosity and reduced expression of the CUTL1 gene in uterine leiomyomas. Oncogene (1997) 0.91
Regulation of the mGluR5, EAAT1 and GS expression by glucocorticoids in MG-63 osteoblast-like osteosarcoma cells. J Musculoskelet Neuronal Interact (2007) 0.91
Characterization of a rabbit antihuman mechano growth factor (MGF) polyclonal antibody against the last 24 amino acids of the E domain. In Vivo (2008) 0.89
The impact of endocrine disruptors on endocrine targets. Horm Metab Res (2010) 0.89
Three-dimensional type I collagen cell culture systems for the study of bone pathophysiology. In Vivo (2005) 0.89
Effects of fibroblasts and basic fibroblast growth factor on facilitation of dermal wound healing by type I collagen matrices. J Biomed Mater Res (1991) 0.88
Development of a parallel plate flow chamber for studying cell behavior under pulsatile flow. ASAIO J (1996) 0.87
Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opin Investig Drugs (2001) 0.87
Expression of functional major histocompatibility complex class II molecules on HMC-1 human mast cells. J Leukoc Biol (1998) 0.87
Prostate cancer cell survival pathways activated by bone metastasis microenvironment. J Musculoskelet Neuronal Interact (2005) 0.86
Plasminogen activator inhibitor 1 messenger RNA expression and molecular evidence for del(7)(q22) in uterine leiomyomas. Cancer Res (1996) 0.85
Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen. Clin Invest Med (1993) 0.84
Microarray analysis of survival pathways in human PC-3 prostate cancer cells. Cancer Genomics Proteomics (2007) 0.84
Three-dimensional type I collagen gel system for the study of osteoblastic metastases produced by metastatic prostate cancer. J Bone Miner Res (1994) 0.84
Surgical stress induces a marked and sustained increase of adrenal androgen secretion in postmenopausal women. In Vivo (1999) 0.83
Stromal fibroblasts are required for PC-3 human prostate cancer cells to produce capillary-like formation of endothelial cells in a three-dimensional co-culture system. Anticancer Res (1997) 0.83
cGMP-independent anti-tumour actions of the inhibitor of soluble guanylyl cyclase, ODQ, in prostate cancer cell lines. Br J Pharmacol (2008) 0.83
Endocrine/paracrine/autocrine survival factor activity of bone microenvironment participates in the development of androgen ablation and chemotherapy refractoriness of prostate cancer metastasis in skeleton. Endocr Relat Cancer (2003) 0.82
Peripheral targets in obesity treatment: a comprehensive update. Obes Rev (2014) 0.82
Three-dimensional type I collagen co-culture systems for the study of cell-cell interactions and treatment response in bone metastases. J Musculoskelet Neuronal Interact (2000) 0.82
Bone microenvironment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells. Horm Metab Res (2005) 0.82
Selective osteoblast mitogens can be extracted from prostatic tissue. Prostate (1986) 0.82
Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat. J Endocrinol (1998) 0.82
Three-dimensional type I collagen gel system containing MG-63 osteoblasts-like cells as a model for studying local bone reaction caused by metastatic cancer cells. Anticancer Res (1996) 0.82
Comparative effects of 28-day treatment with the new anti-estrogen EM-800 and tamoxifen on estrogen-sensitive parameters in intact mice. Int J Cancer (1997) 0.81
Chemotherapy cytotoxicity of human MCF-7 and MDA-MB 231 breast cancer cells is altered by osteoblast-derived growth factors. Mol Med (1999) 0.81
The role of urokinase-type plasminogen activator (uPA) and transforming growth factor beta 1 (TGFbeta1) in muscle regeneration. In Vivo (2009) 0.81
Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(A)anthracene-induced mammary carcinoma in the rat. Endocrinology (1997) 0.81
Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells. Prostate (1995) 0.80
Mechanisms of the action of zoledronic acid on human MG-63 osteosarcoma cells. Horm Metab Res (2008) 0.80
Changes in the mechanical properties of human quadriceps muscle after eccentric exercise. In Vivo (2009) 0.80
Human endometrial cells cultured in a type I collagen gel. J Reprod Med (1996) 0.80
Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma. Prostate (1983) 0.80
Carotid body paraganglioma and SDHD mutation in a Greek family. Anticancer Res (2005) 0.79
Studies of the multiple molecular forms of bioactive parathyroid hormone and parathyroid hormone-like substances. Recent Prog Horm Res (1986) 0.79
Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration. J Steroid Biochem (1983) 0.79
Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen. Clin Exp Metastasis (1999) 0.79
Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: classification of variables associated with disease outcome. Prostate (1985) 0.79
Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy. Anticancer Res (1997) 0.78
Mediation of glucocorticoid receptor function by the activation of latent transforming growth factor beta 1 in MG-63 human osteosarcoma cells. Int J Cancer (1995) 0.78
Interaction of antiandrogen-androgen receptor complexes with DNA and transcription activation. J Steroid Biochem Mol Biol (1993) 0.78
Course of the initial epithelial lesions associated with autologous bile duct replacement. Experimental study in rats. Am J Surg (1981) 0.78
Increased insulin-like growth factor 1 activity can rescue KLE endometrial-like cells from apoptosis. Mol Med (2001) 0.78
Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP. Prostate (1994) 0.78
Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma. Br J Urol (1993) 0.78
Immunohistochemical localization of insulin-like growth factor-binding protein-3 in eutopic and ectopic endometrial tissues. Fertil Steril (1999) 0.78
Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer. Anticancer Res (1997) 0.77
A model for laparoscopic aortic aneurysm resection. Surg Endosc (1999) 0.76
Osteoblast-derived growth factors enhance adriamycin-cytostasis of MCF-7 human breast cancer cells. Anticancer Res (1999) 0.76
KISS1/KISS1R expression in eutopic and ectopic endometrium of women suffering from endometriosis. In Vivo (2012) 0.76
Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogen-sensitive parameters in intact and ovariectomized mice. Endocrinology (1998) 0.76
Metastatic prostate cancer: hormone dependency and therapeutic efficacy of GnRH analogues. Acta Endocrinol Suppl (Copenh) (1984) 0.75
Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton. Clin Exp Metastasis (1997) 0.75
Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients. Anticancer Res (2002) 0.75
Purification and partial sequencing of the major mitogen for human uterine smooth muscle-like cells in leiomyoma extracts. J Clin Invest (1995) 0.75
Cancer and bone repair mechanism: clinical applications for hormone refractory prostate cancer. J Musculoskelet Neuronal Interact (2000) 0.75
Fetal pancreatic transplantation--review of experimental data. Transplant Proc (1980) 0.75
Skeletal growth factor involvement in the regulation of fracture healing process. In Vivo (2003) 0.75
In vitro exposure of a novel polyesterurethane graft to enzymes: a study of the biostability of the Vascugraft arterial prosthesis. Biomaterials (1994) 0.75
Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases. Anticancer Res (2004) 0.75
Molecular diagnosis of the viral component in cardiomyopathies: pathophysiological, clinical and therapeutic implications. Expert Opin Ther Targets (2008) 0.75
Combinational effect of topotecan and octreotide on murine leukemia cells in vivo and in vitro. J BUON (2007) 0.75
Impregnated polyester arterial prostheses: performance and prospects. Ann Vasc Surg (1999) 0.75
Characterization of KW smooth muscle-like human myometrial cells. Anticancer Res (1995) 0.75
Dexamethasone plus octreotide regimen increases anticancer effects of docetaxel on TRAMP-C1 prostate cancer model. In Vivo (2012) 0.75
Positive urinary cytology in patients with lung cancer in the absence of obvious urine tract metastases. Lung Cancer (2010) 0.75
Response of PC-3 prostate cancer cells to combination therapy using irradiation with glucocorticoids or doxorubicin. Anticancer Res (2000) 0.75
The quarrel between iatromechanists and animists about the cause of cancer: lymph's role in oncogenesis. J BUON (2012) 0.75
Complete response of lung metastases caused by prostatic cancer after chronic administration of a gonadotropin-releasing hormone analog, buserelin (HOE 766). Prostate (1987) 0.75
The role of kisspeptin/GPR54 in the reproductive system. In Vivo (2011) 0.75
Effects of glycerol pretreatment upon biliary or venous grafts in bile duct replacement. Surg Gynecol Obstet (1981) 0.75
Extraskeletal Ewing's sarcoma. Presentation of two cases and review of the literature. Eur J Surg Oncol (1991) 0.75
Advanced prostatic adenocarcinoma: biological aspects and effects of androgen deprivation achieved by castration or agonistic analogues of LHRH. Med Oncol Tumor Pharmacother (1984) 0.75
Transphenoidal removal of GH secreting adenomas: method of choice for the treatment of acromegaly. Acta Endocrinol Suppl (Copenh) (1984) 0.75
Experimental laparoscopic aortobifemoral bypass with end-to-side aortic anastomosis. Surg Laparosc Endosc (1999) 0.75